| Year |
Citation |
Score |
| 2024 |
Reavis HD, Gysler SM, McKenney GB, Knarr M, Lusk HJ, Rawat P, Rendulich HS, Mitchell MA, Berger DS, Moon JS, Ryu S, Mainigi M, Iwanicki MP, Hoon DS, Sanchez LM, ... Drapkin R, et al. Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells. Jci Insight. PMID 38271085 DOI: 10.1172/jci.insight.170961 |
0.323 |
|
| 2023 |
Bustos MA, Yokoe T, Shoji Y, Kobayashi Y, Mizuno S, Murakami T, Zhang X, Sekhar SC, Kim S, Ryu S, Knarr M, Vasilev SA, DiFeo A, Drapkin R, Hoon DSB. MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer. Cell & Bioscience. 13: 200. PMID 37932806 DOI: 10.1186/s13578-023-01151-y |
0.352 |
|
| 2023 |
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, ... ... Drapkin R, et al. Dual blockade of BRD4 and ATR/WEE1 pathways exploits loss in clear cell ovarian cancer. Research Square. PMID 37841875 DOI: 10.21203/rs.3.rs-3314138/v1 |
0.383 |
|
| 2023 |
Taylor MS, Wu C, Fridy PC, Zhang SJ, Senussi Y, Wolters JC, Cajuso T, Cheng WC, Heaps JD, Miller BD, Mori K, Cohen L, Jiang H, Molloy KR, Chait BT, ... ... Drapkin R, et al. Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. Cancer Discovery. PMID 37698949 DOI: 10.1158/2159-8290.CD-23-0313 |
0.396 |
|
| 2023 |
Ferrari AJ, Rawat P, Rendulich HS, Annapragada AV, Kinose Y, Zhang X, Devins K, Budina A, Scharpf RB, Mitchell MA, Tanyi JL, Morgan MA, Schwartz LE, Soong TR, Velculescu VE, ... Drapkin R, et al. H2Bub1 loss is an early contributor to clear cell ovarian cancer progression. Jci Insight. 8. PMID 37345659 DOI: 10.1172/jci.insight.164995 |
0.381 |
|
| 2023 |
Nameki RA, Chang H, Yu P, Abbasi F, Lin X, Reddy J, Haro M, Fonseca MA, Freedman ML, Drapkin R, Corona RI, Lawrenson K. Rewiring of master transcription factor cistromes during high-grade serous ovarian cancer development. Biorxiv : the Preprint Server For Biology. PMID 37090516 DOI: 10.1101/2023.04.11.536378 |
0.327 |
|
| 2023 |
Taylor MS, Wu C, Fridy PC, Senussi Y, Cheng WC, Heaps J, Mori K, Cohen L, Molloy KR, Chait BT, Goggins M, Bhan I, Franses JW, Yang X, Taplin ME, ... ... Drapkin R, et al. Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. Biorxiv : the Preprint Server For Biology. PMID 36747644 DOI: 10.1101/2023.01.25.525462 |
0.379 |
|
| 2023 |
Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, Feng Y, Mendez-Dorantes C, Ippoliti PJ, Hobday S, Mitchell MA, Doberstein K, Gysler SM, Hirsch MS, Schwartz L, ... ... Drapkin R, et al. LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. Scientific Reports. 13: 1537. PMID 36707610 DOI: 10.1038/s41598-023-28840-5 |
0.627 |
|
| 2022 |
Doberstein K, Spivak R, Reavis HD, Hooda J, Feng Y, Kroeger PT, Stuckelberger S, Mills GB, Devins KM, Schwartz LE, Iwanicki MP, Fogel M, Altevogt P, Drapkin R. L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary. Communications Biology. 5: 1362. PMID 36509990 DOI: 10.1038/s42003-022-04314-8 |
0.321 |
|
| 2022 |
Banerjee S, Drapkin R, Richardson DL, Birrer M. Targeting NaPi2b in ovarian cancer. Cancer Treatment Reviews. 112: 102489. PMID 36446254 DOI: 10.1016/j.ctrv.2022.102489 |
0.442 |
|
| 2022 |
Madan E, Palma AM, Vudatha V, Trevino JG, Natarajan KN, Winn RA, Won KJ, Graham TA, Drapkin R, McDonald SA, Fisher PB, Gogna R. Cell competition in carcinogenesis. Cancer Research. PMID 36214625 DOI: 10.1158/0008-5472.CAN-22-2217 |
0.363 |
|
| 2022 |
Chaves-Moreira D, Mitchell MA, Arruza C, Rawat P, Sidoli S, Nameki R, Reddy J, Corona RI, Afeyan LK, Klein IA, Ma S, Winterhoff B, Konecny GE, Garcia BA, Brady DC, ... ... Drapkin R, et al. The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17. Science Signaling. 15: eabm2496. PMID 35380877 DOI: 10.1126/scisignal.abm2496 |
0.44 |
|
| 2021 |
Cunningham JM, Winham SJ, Wang C, Weigelt B, Fu Z, Armasu SM, McCauley BM, Brand AH, Chiew YE, Elishaev E, Gourley C, Kennedy CJ, Laslvic A, Lester J, Piskorz A, ... ... Drapkin R, et al. DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 34697060 DOI: 10.1158/1055-9965.EPI-21-0677 |
0.363 |
|
| 2021 |
Xu H, George E, Kinose Y, Kim H, Shah JB, Peake JD, Ferman B, Medvedev S, Murtha T, Barger CJ, Devins KM, D'Andrea K, Wubbenhorst B, Schwartz LE, Hwang WT, ... ... Drapkin R, et al. copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Reports. Medicine. 2: 100394. PMID 34622231 DOI: 10.1016/j.xcrm.2021.100394 |
0.352 |
|
| 2021 |
Lecker LS, Berlato C, Maniati E, Delaine-Smith R, Pearce OMT, Heath O, Nichols SJ, Trevisan C, Novak M, McDermott J, Brenton JD, Cutillas PR, Rajeeve V, Hennino A, Drapkin R, et al. TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer. Cancer Research. PMID 34561272 DOI: 10.1158/0008-5472.CAN-21-0536 |
0.333 |
|
| 2021 |
Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, Liu H, Fatkhutdinov N, Zundell JA, Karakashev S, Zhou W, Schwartz LE, Tang HY, Drapkin R, Liu Q, et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nature Cancer. 2: 189-200. PMID 34085048 DOI: 10.1038/s43018-020-00160-x |
0.314 |
|
| 2021 |
Gysler SM, Drapkin R. Tumor innervation: peripheral nerves take control of the tumor microenvironment. The Journal of Clinical Investigation. 131. PMID 34060481 DOI: 10.1172/JCI147276 |
0.312 |
|
| 2021 |
Barger CJ, Chee L, Albahrani M, Munoz-Trujillo C, Boghean L, Branick C, Odunsi K, Drapkin R, Zou L, Karpf AR. Co-regulation and function of / bidirectional genes in cancer. Elife. 10. PMID 33890574 DOI: 10.7554/eLife.55070 |
0.432 |
|
| 2021 |
Mauro LJ, Seibel MI, Diep CH, Spartz A, Perez Kerkvliet C, Singhal H, Swisher EM, Schwartz LE, Drapkin R, Saini S, Sesay F, Litovchick L, Lange CA. Progesterone Receptors Promote Quiescence & Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models. The Journal of Clinical Endocrinology and Metabolism. PMID 33755733 DOI: 10.1210/clinem/dgab195 |
0.309 |
|
| 2021 |
Tangri A, Lighty K, Loganathan J, Mesmar F, Podicheti R, Zhang C, Iwanicki M, Drapkin R, Nakshatri H, Mitra S. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-Grade Serous Ovarian Carcinoma. Molecular Cancer Research : McR. PMID 33753553 DOI: 10.1158/1541-7786.MCR-20-0883 |
0.38 |
|
| 2021 |
Burston HE, Kent OA, Communal L, Udaskin ML, Sun RX, Brown KR, Jung E, Francis KE, La Rose J, Lowitz JK, Drapkin R, Mes-Masson AM, Rottapel R. Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. The Journal of Clinical Investigation. PMID 33561012 DOI: 10.1172/JCI142677 |
0.398 |
|
| 2021 |
Ferrari AJ, Drapkin R, Gogna R. Cell Fitness: More Than Push-Ups. International Journal of Molecular Sciences. 22. PMID 33430180 DOI: 10.3390/ijms22020518 |
0.38 |
|
| 2021 |
Chaves-Moreira D, Morin PJ, Drapkin R. Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers. Cancer Research. 81: 806-810. PMID 33361393 DOI: 10.1158/0008-5472.CAN-20-3173 |
0.431 |
|
| 2020 |
Lv X, He C, Huang C, Hua G, Chen X, Timm BK, Maclin VM, Haggerty AA, Aust SK, Golden DM, Dave BJ, Tseng YA, Chen L, Wang H, Chen P, ... ... Drapkin RI, et al. Reprogramming of Ovarian Granulosa Cells by YAP1 Leads to Development of High-Grade Cancer with Mesenchymal Lineage and Serous Features. Science Bulletin. 65: 1281-1296. PMID 34888112 DOI: 10.1016/j.scib.2020.03.040 |
0.446 |
|
| 2020 |
Pierini S, Tanyi JL, Simpkins F, George E, Uribe-Herranz M, Drapkin R, Burger R, Morgan MA, Facciabene A. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. Jci Insight. 5. PMID 32814714 DOI: 10.1172/jci.insight.136773 |
0.322 |
|
| 2020 |
Kim O, Park EY, Klinkebiel DL, Pack SD, Shin YH, Abdullaev Z, Emerson RE, Coffey DM, Kwon SY, Creighton CJ, Kwon S, Chang EC, Chiang T, Yatsenko AN, Chien J, ... ... Drapkin R, et al. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. Plos Genetics. 16: e1008808. PMID 32497036 DOI: 10.1371/Journal.Pgen.1008808 |
0.419 |
|
| 2020 |
Suryo Rahmanto Y, Shen W, Shi X, Chen X, Yu Y, Yu ZC, Miyamoto T, Lee MH, Singh V, Asaka R, Shimberg G, Vitolo MI, Martin SS, Wirtz D, Drapkin R, et al. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nature Communications. 11: 2717. PMID 32483112 DOI: 10.1038/S41467-020-16416-0 |
0.357 |
|
| 2020 |
Ding B, Yuan F, Damle PK, Litovchick L, Drapkin R, Grossman SR. CtBP determines ovarian cancer cell fate through repression of death receptors. Cell Death & Disease. 11: 286. PMID 32332713 DOI: 10.1038/S41419-020-2455-7 |
0.404 |
|
| 2020 |
Reavis HD, Drapkin R. The tubal epigenome - An emerging target for ovarian cancer. Pharmacology & Therapeutics. 210: 107524. PMID 32197795 DOI: 10.1016/j.pharmthera.2020.107524 |
0.421 |
|
| 2020 |
Maniati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, McDermott J, Pegrum C, Delaine-Smith RM, Pearce OMT, Hirani P, Joy JD, Szabova L, Perets R, Sansom OJ, ... Drapkin R, et al. Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment. Cell Reports. 30: 525-540.e7. PMID 31940494 DOI: 10.1016/j.celrep.2019.12.034 |
0.337 |
|
| 2019 |
Lawrenson K, Fonseca MAS, Liu AY, Segato Dezem F, Lee JM, Lin X, Corona RI, Abbasi F, Vavra KC, Dinh HQ, Gill NK, Seo JH, Coetzee S, Lin YG, Pejovic T, ... ... Drapkin R, et al. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development. Cell Reports. 29: 3726-3735.e4. PMID 31825847 DOI: 10.1016/J.Celrep.2019.10.122 |
0.36 |
|
| 2019 |
Bai S, Zhu W, Coffman L, Vlad A, Schwartz LE, Elishaev E, Drapkin R, Buckanovich RJ. CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary. Cancers. 11. PMID 31684072 DOI: 10.3390/Cancers11111710 |
0.319 |
|
| 2019 |
Reavis H, Drapkin R. H2Bub1: Guardian of chromatin accessibility in ovarian cancer. Oncoscience. 6: 349-350. PMID 31608296 DOI: 10.18632/oncoscience.484 |
0.367 |
|
| 2019 |
Chui MH, Doodnauth SA, Erdmann N, Tiedemann RE, Sircoulomb F, Drapkin R, Shaw P, Rottapel R. Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma. Cancer Research. PMID 31530568 DOI: 10.1158/0008-5472.Can-18-3029 |
0.386 |
|
| 2019 |
Zhao B, Lin J, Rong L, Wu S, Deng Z, Fatkhutdinov N, Zundell J, Fukumoto T, Liu Q, Kossenkov A, Jean S, Cadungog MG, Borowsky ME, Drapkin R, Lieberman PM, et al. ARID1A promotes genomic stability through protecting telomere cohesion. Nature Communications. 10: 4067. PMID 31492885 DOI: 10.1038/S41467-019-12037-4 |
0.337 |
|
| 2019 |
Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, et al. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. PMID 30835824 DOI: 10.1002/Cncr.32004 |
0.349 |
|
| 2018 |
Hooda J, Novak M, Salomon MP, Matsuba C, Ramos RI, MacDuffie E, Song M, Hirsch MS, Lester J, Parkash V, Karlan BY, Oren M, Hoon DS, Drapkin R. Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Research. PMID 30563893 DOI: 10.1158/0008-5472.Can-18-2297 |
0.361 |
|
| 2018 |
Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M, Kagiampakis I, Palsgrove D, Conklin D, Kinose Y, White JR, Press MF, Drapkin R, Easwaran H, Baylin SB, et al. Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Reports. 25: 2617-2633. PMID 30485824 DOI: 10.1016/J.Celrep.2018.10.096 |
0.419 |
|
| 2018 |
Barger CJ, Zhang W, Sharma A, Chee L, James SR, Kufel CN, Miller A, Meza J, Drapkin R, Odunsi K, Klinkebiel D, Karpf AR. Expression of the POTE gene family in human ovarian cancer. Scientific Reports. 8: 17136. PMID 30459449 DOI: 10.1038/s41598-018-35567-1 |
0.422 |
|
| 2018 |
Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW. CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Scientific Reports. 8: 14725. PMID 30282979 DOI: 10.1038/S41598-018-32885-2 |
0.316 |
|
| 2018 |
Elias KM, Tsantoulis P, Tille JC, Vitonis A, Doyle LA, Hornick JL, Kaya G, Barnes L, Cramer DW, Puppa G, Stuckelberger S, Hooda J, Dietrich PY, Goggins M, Kerr CL, ... ... Drapkin R, et al. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. The Journal of Pathology. PMID 30229909 DOI: 10.1002/path.5161 |
0.344 |
|
| 2018 |
Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, ... Drapkin R, et al. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology. PMID 29572027 DOI: 10.1016/J.Ygyno.2018.03.050 |
0.38 |
|
| 2018 |
Stuckelberger S, Drapkin R. Precious GEMMs: emergence of faithful models for ovarian cancer research. The Journal of Pathology. 245: 129-131. PMID 29493783 DOI: 10.1002/path.5065 |
0.37 |
|
| 2018 |
Karakashev S, Zhu H, Wu S, Yokoyama Y, Bitler BG, Park PH, Lee JH, Kossenkov AV, Gaonkar KS, Yan H, Drapkin R, Conejo-Garcia JR, Speicher DW, Ordog T, Zhang R. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nature Communications. 9: 631. PMID 29434212 DOI: 10.1038/S41467-018-03031-3 |
0.438 |
|
| 2017 |
Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, ... ... Drapkin R, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications. 8: 1093. PMID 29061967 DOI: 10.1038/S41467-017-00962-1 |
0.408 |
|
| 2017 |
Zervantonakis IK, Iavarone C, Chen HY, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Leverson JD, Sampath D, Mills GB, Brugge JS. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nature Communications. 8: 365. PMID 28848242 DOI: 10.1038/S41467-017-00263-7 |
0.324 |
|
| 2017 |
Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, ... ... Drapkin R, et al. PRKCI promotes immune suppression in ovarian cancer. Genes & Development. PMID 28698296 DOI: 10.1101/Gad.296640.117 |
0.46 |
|
| 2017 |
Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, et al. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016703439. PMID 28398847 DOI: 10.1200/Jco.2016.70.3439 |
0.315 |
|
| 2017 |
Medrano M, Communal L, Brown KR, Iwanicki M, Normand J, Paterson J, Sircoulomb F, Krzyzanowski P, Novak M, Doodnauth SA, Saiz FS, Cullis J, Al-Awar R, Neel BG, McPherson J, ... Drapkin R, et al. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. Cell Reports. 18: 2343-2358. PMID 28273451 DOI: 10.1016/J.Celrep.2017.02.028 |
0.337 |
|
| 2017 |
George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, ... ... Drapkin R, et al. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. Jci Insight. 2: e89760. PMID 28097235 DOI: 10.1172/Jci.Insight.89760 |
0.367 |
|
| 2017 |
Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Current Opinion in Obstetrics & Gynecology. 29: 26-34. PMID 27898521 DOI: 10.1097/GCO.0000000000000340 |
0.415 |
|
| 2016 |
Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD. Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27663592 DOI: 10.1158/1078-0432.CCR-16-0620 |
0.325 |
|
| 2016 |
Elias KM, Emori MM, Westerling T, Long H, Budina-Kolomets A, Li F, MacDuffie E, Davis MR, Holman A, Lawney B, Freedman ML, Quackenbush J, Brown M, Drapkin R. Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. Jci Insight. 1. PMID 27617304 DOI: 10.1172/Jci.Insight.87988 |
0.549 |
|
| 2016 |
Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, ... ... Drapkin R, et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27573169 DOI: 10.1158/1078-0432.Ccr-16-1237 |
0.554 |
|
| 2016 |
Wang S, Blois A, El Rayes T, Liu JF, Hirsch MS, Gravdal K, Palakurthi S, Bielenberg DR, Akslen LA, Drapkin R, Mittal V, Watnick RS. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Science Translational Medicine. 8: 329ra34. PMID 26962158 DOI: 10.1126/Scitranslmed.Aad5653 |
0.363 |
|
| 2015 |
Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, ... ... Drapkin RI, et al. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. PMID 26686630 DOI: 10.1016/J.Celrep.2015.11.047 |
0.418 |
|
| 2015 |
Feng Y, Doberstein K, Drapkin R. Elafin: a double agent in breast and ovarian cancer. Oncoscience. 2: 793-4. PMID 26682248 |
0.354 |
|
| 2015 |
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews. Cancer. 15: 668-79. PMID 26493647 DOI: 10.1038/Nrc4019 |
0.366 |
|
| 2015 |
Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE, Drapkin R. Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. Gynecologic Oncology. 139: 97-103. PMID 26321251 DOI: 10.1016/J.Ygyno.2015.08.017 |
0.347 |
|
| 2015 |
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, ... ... Drapkin R, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 521: 489-94. PMID 26017449 DOI: 10.1038/Nature14410 |
0.306 |
|
| 2015 |
Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, Skates S, Birrer M. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4960-9. PMID 25944803 DOI: 10.1158/1078-0432.Ccr-14-3173 |
0.384 |
|
| 2015 |
Coetzee SG, Shen HC, Hazelett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J, Rhie SK, Levanon K, Karst A, Drapkin R, Ramus SJ, Couch FJ, Offit K, Chenevix-Trench G, et al. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics. 24: 3595-607. PMID 25804953 DOI: 10.1093/Hmg/Ddv101 |
0.391 |
|
| 2015 |
Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 160: 977-89. PMID 25723171 DOI: 10.1016/J.Cell.2015.01.042 |
0.537 |
|
| 2015 |
Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC, Kung AL, Beroukhim R, Bradner JE, Drapkin R, Hahn WC, Liu JF, et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 112: 232-7. PMID 25535366 DOI: 10.1073/Pnas.1422165112 |
0.714 |
|
| 2014 |
Emori MM, Drapkin R. The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. Reproductive Biology and Endocrinology : Rb&E. 12: 60. PMID 24997727 DOI: 10.1186/1477-7827-12-60 |
0.346 |
|
| 2014 |
Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. The Journal of Clinical Investigation. 124: 2611-25. PMID 24762435 DOI: 10.1172/Jci69815 |
0.46 |
|
| 2014 |
Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, ... ... Drapkin R, et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proceedings of the National Academy of Sciences of the United States of America. 111: 1102-7. PMID 24385586 DOI: 10.1073/Pnas.1311909111 |
0.451 |
|
| 2014 |
Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, Etemadmoghadam D, Bowtell DD, Drapkin R. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Research. 74: 1141-52. PMID 24366882 DOI: 10.1158/0008-5472.CAN-13-2247 |
0.361 |
|
| 2013 |
Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, ... Drapkin R, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 24: 751-65. PMID 24332043 DOI: 10.1016/j.ccr.2013.10.013 |
0.42 |
|
| 2013 |
Li J, Chen H, Mariani A, Chen D, Klatt E, Podratz K, Drapkin R, Broaddus R, Dowdy S, Jiang SW. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. International Journal of Molecular Sciences. 14: 6026-43. PMID 23502467 DOI: 10.3390/ijms14036026 |
0.454 |
|
| 2013 |
Sung CK, Li D, Andrews E, Drapkin R, Benjamin T. Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers. Molecular Oncology. 7: 419-27. PMID 23273547 DOI: 10.1016/J.Molonc.2012.11.005 |
0.362 |
|
| 2013 |
Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, ... ... Drapkin R, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. The Journal of Clinical Investigation. 123: 517-25. PMID 23257362 DOI: 10.1172/Jci65833 |
0.312 |
|
| 2013 |
O'Neal RL, Nam KT, LaFleur BJ, Barlow B, Nozaki K, Lee HJ, Kim WH, Yang HK, Shi C, Maitra A, Montgomery E, Washington MK, El Rifai W, Drapkin RI, Goldenring JR. Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. Human Pathology. 44: 734-42. PMID 23084584 DOI: 10.1016/J.Humpath.2012.07.017 |
0.338 |
|
| 2012 |
Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5806-15. PMID 22912389 DOI: 10.1158/1078-0432.Ccr-12-0857 |
0.32 |
|
| 2012 |
Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Science Translational Medicine. 4: 147ra112. PMID 22896676 DOI: 10.1126/Scitranslmed.3003778 |
0.408 |
|
| 2012 |
Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, Quackenbush J, Matulonis UA. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. Plos One. 7: e30269. PMID 22348002 DOI: 10.1371/Journal.Pone.0030269 |
0.446 |
|
| 2012 |
Vermeer PD, Bell M, Lee K, Vermeer DW, Wieking BG, Bilal E, Bhanot G, Drapkin RI, Ganesan S, Klingelhutz AJ, Hendriks WJ, Lee JH. ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers. Plos One. 7: e30447. PMID 22279592 DOI: 10.1371/Journal.Pone.0030447 |
0.306 |
|
| 2012 |
Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, Jiang SW, Podratz K, Urban N, Dowdy SC. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer Gynecologic Oncology. 124: 270-275. PMID 22037318 DOI: 10.1016/j.ygyno.2011.10.025 |
0.328 |
|
| 2011 |
Karst AM, Drapkin R. The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Medicine Reports. 3: 22. PMID 22076125 DOI: 10.3410/M3-22 |
0.367 |
|
| 2011 |
Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (New York, N.Y.). 334: 1129-33. PMID 22033517 DOI: 10.1126/Science.1206727 |
0.539 |
|
| 2011 |
Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews. Cancer. 11: 719-25. PMID 21941283 DOI: 10.1038/Nrc3144 |
0.313 |
|
| 2011 |
Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, van Hummelen P, MacConaill L, Drapkin R, Hahn WC. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. Plos One. 6: e24433. PMID 21931712 DOI: 10.1371/Journal.Pone.0024433 |
0.375 |
|
| 2011 |
Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, ... ... Drapkin R, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 108: 12372-7. PMID 21746896 DOI: 10.1073/Pnas.1109363108 |
0.461 |
|
| 2011 |
Fotheringham S, Levanon K, Drapkin R. Ex vivo culture of primary human fallopian tube epithelial cells. Journal of Visualized Experiments : Jove. PMID 21610668 DOI: 10.3791/2728 |
0.452 |
|
| 2011 |
Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, Crum CP. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Frontiers in Bioscience (Elite Edition). 3: 625-34. PMID 21196340 |
0.371 |
|
| 2010 |
Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Structural & Molecular Biology. 17: 688-95. PMID 20453858 DOI: 10.1038/Nsmb.1831 |
0.423 |
|
| 2010 |
Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, Zaghlul S, Batt D, Ettenberg S, Meyerson M, Schoeberl B, ... ... Drapkin R, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 17: 298-310. PMID 20227043 DOI: 10.1016/J.Ccr.2009.12.047 |
0.615 |
|
| 2010 |
Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia (New York, N.Y.). 12: 161-72. PMID 20126474 DOI: 10.1593/NEO.91542 |
0.432 |
|
| 2009 |
Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 55: 619. PMID 19912369 DOI: 10.1111/j.1365-2559.2009.03408.x |
0.359 |
|
| 2009 |
Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. Journal of Oncology. 2010: 932371. PMID 19746182 DOI: 10.1155/2010/932371 |
0.396 |
|
| 2008 |
Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact Journal of Clinical Oncology. 26: 5284-5293. PMID 18854563 DOI: 10.1200/JCO.2008.18.1107 |
0.377 |
|
| 2008 |
De Nicolo A, Tancredi M, Lombardi G, Flemma CC, Barbuti S, Di Cristofano C, Sobhian B, Bevilacqua G, Drapkin R, Caligo MA. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4672-80. PMID 18628483 DOI: 10.1158/1078-0432.CCR-08-0087 |
0.357 |
|
| 2007 |
Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clinical Medicine & Research. 5: 35-44. PMID 17456833 DOI: 10.3121/cmr.2007.702 |
0.37 |
|
| 2007 |
Silver DP, Dimitrov SD, Feunteun J, Gelman R, Drapkin R, Lu SD, Shestakova E, Velmurugan S, Denunzio N, Dragomir S, Mar J, Liu X, Rottenberg S, Jonkers J, Ganesan S, et al. Further evidence for BRCA1 communication with the inactive X chromosome. Cell. 128: 991-1002. PMID 17350581 DOI: 10.1016/J.Cell.2007.02.025 |
0.666 |
|
| 2007 |
Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, ... ... Drapkin RI, et al. A recurrent mutation in PALB2 in Finnish cancer families Nature. 446: 316-319. PMID 17287723 DOI: 10.1038/Nature05609 |
0.551 |
|
| 2005 |
Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Research. 65: 2162-9. PMID 15781627 DOI: 10.1158/0008-5472.CAN-04-3924 |
0.396 |
|
| 2005 |
Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, Jenuwein T, Livingston DM, Rajewsky K. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes & Development. 19: 489-501. PMID 15713842 DOI: 10.1101/Gad.1248505 |
0.48 |
|
| 2004 |
Drapkin R, Crum CP, Hecht JL. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Human Pathology. 35: 1014-21. PMID 15297969 DOI: 10.1016/j.humpath.2004.04.014 |
0.309 |
|
| 2004 |
Ganesan S, Silver DP, Drapkin R, Greenberg R, Feunteun J, Livingston DM. Association of BRCA1 with the inactive X chromosome and XIST RNA. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 359: 123-8. PMID 15065664 DOI: 10.1098/Rstb.2003.1371 |
0.697 |
|
| 2004 |
Cantor S, Drapkin R, Zhang F, Lin Y, Han J, Pamidi S, Livingston DM. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations Proceedings of the National Academy of Sciences of the United States of America. 101: 2357-2362. PMID 14983014 DOI: 10.1073/Pnas.0308717101 |
0.703 |
|
| 2002 |
Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, Randrianarison V, Brodie S, Salstrom J, Rasmussen TP, Klimke A, Marrese C, Marahrens Y, Deng CX, et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell. 111: 393-405. PMID 12419249 DOI: 10.1016/S0092-8674(02)01052-8 |
0.688 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2023 |
Zhou W, Liu H, Yuan Z, Zundell J, Towers M, Lin J, Lombardi S, Nie H, Murphy B, Yang T, Wang C, Liao L, Goldman AR, Kannan T, Kossenkov AV, ... Drapkin R, et al. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell. PMID 36963401 DOI: 10.1016/j.ccell.2023.03.002 |
0.298 |
|
| 2014 |
Baldwin LA, Hoff JT, Lefringhouse J, Zhang M, Jia C, Liu Z, Erfani S, Jin H, Xu M, She QB, van Nagell JR, Wang C, Chen L, Plattner R, Kaetzel DM, ... ... Drapkin R, et al. CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. Oncotarget. 5: 12203-17. PMID 25356755 DOI: 10.18632/Oncotarget.2622 |
0.296 |
|
| 2019 |
Rentchler EC, Gant KL, Drapkin R, Patankar M, J Campagnola P. Imaging Collagen Alterations in STICs and High Grade Ovarian Cancers in the Fallopian Tubes by Second Harmonic Generation Microscopy. Cancers. 11. PMID 31744173 DOI: 10.3390/Cancers11111805 |
0.295 |
|
| 2007 |
Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Current Opinion in Obstetrics & Gynecology. 19: 3-9. PMID 17218844 DOI: 10.1097/GCO.0b013e328011a21f |
0.293 |
|
| 2011 |
Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS. A comprehensive analysis of PAX8 expression in human epithelial tumors. The American Journal of Surgical Pathology. 35: 816-26. PMID 21552115 DOI: 10.1097/PAS.0b013e318216c112 |
0.293 |
|
| 2019 |
Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, et al. Phase II, 2-Stage, 2-Arm, PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent Endometrial Cancer. International Journal of Cancer. PMID 31714586 DOI: 10.1002/Ijc.32783 |
0.289 |
|
| 2012 |
Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Allred SF, Gross J, Deavers MT, Kuo WL, Karlan BY, Rueda BR, Orsulic S, Gershenson DM, Birrer MJ, et al. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. Plos One. 7: e30996. PMID 22355333 DOI: 10.1371/Journal.Pone.0030996 |
0.289 |
|
| 2016 |
Iwanicki MP, Chen HY, Iavarone C, Zervantonakis IK, Muranen T, Novak M, Ince TA, Drapkin R, Brugge JS. Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. Jci Insight. 1. PMID 27482544 DOI: 10.1172/Jci.Insight.86829 |
0.288 |
|
| 2021 |
Barr JL, Kruse A, Restaino AC, Tulina N, Stuckelberger S, Vermeer SJ, Williamson CS, Vermeer DW, Madeo M, Stamp J, Bell M, Morgan M, Yoon JY, Mitchell MA, Budina A, ... ... Drapkin R, et al. Intra-Tumoral Nerve-Tracing in a Novel Syngeneic Model of High-Grade Serous Ovarian Carcinoma. Cells. 10. PMID 34944001 DOI: 10.3390/cells10123491 |
0.287 |
|
| 2021 |
Reddy J, Fonseca MAS, Corona RI, Nameki R, Segato Dezem F, Klein IA, Chang H, Chaves-Moreira D, Afeyan LK, Malta TM, Lin X, Abbasi F, Font-Tello A, Sabedot T, Cejas P, ... ... Drapkin R, et al. Predicting master transcription factors from pan-cancer expression data. Science Advances. 7: eabf6123. PMID 34818047 DOI: 10.1126/sciadv.abf6123 |
0.287 |
|
| 2008 |
Girnun GD, Chen L, Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, Li D, Force J, McNamara K, et al. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6478-86. PMID 18927287 DOI: 10.1158/1078-0432.Ccr-08-1128 |
0.283 |
|
| 2023 |
Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, et al. Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37097611 DOI: 10.1158/1078-0432.CCR-22-2444 |
0.282 |
|
| 2022 |
Liu H, Lin J, Zhou W, Moses R, Dai Z, Kossenkov AV, Drapkin R, Bitler BG, Karakashev S, Zhang R. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. Cancer Immunology Research. OF1-OF11. PMID 35726891 DOI: 10.1158/2326-6066.CIR-22-0088 |
0.28 |
|
| 2015 |
Howitt BE, Emori MM, Drapkin R, Gaspar C, Barletta JA, Nucci MR, McCluggage WG, Oliva E, Hirsch MS. GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract. The American Journal of Surgical Pathology. 39: 1411-9. PMID 26135559 DOI: 10.1097/PAS.0000000000000471 |
0.278 |
|
| 2021 |
Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, Morgan M, Burger RA, Haggerty A, Zarrin H, Rodriguez D, Domchek S, Drapkin R, Shih IM, Smith SA, et al. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic Oncology. PMID 34620496 DOI: 10.1016/j.ygyno.2021.08.024 |
0.277 |
|
| 2019 |
Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Leverson JD, Sampath D, Mills GB, Brugge JS. Combined MEK and BCL-2/XL inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and BIM levels are predictive of responsiveness. Molecular Cancer Therapeutics. PMID 30679390 DOI: 10.1158/1535-7163.Mct-18-0413 |
0.275 |
|
| 2010 |
Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, Hirsch MS. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. The American Journal of Surgical Pathology. 34: 627-35. PMID 20414098 DOI: 10.1097/PAS.0b013e3181da7687 |
0.272 |
|
| 2011 |
Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proceedings of the National Academy of Sciences of the United States of America. 108: 7547-52. PMID 21502498 DOI: 10.1073/pnas.1017300108 |
0.27 |
|
| 2019 |
Beirne JP, McArt DG, Roddy A, McDermott C, Ferris J, Buckley NE, Coulter P, McCabe N, Eddie SL, Dunne PD, O'Reilly P, Gilmore A, Feeney L, Ewing DL, Drapkin RI, et al. Defining the molecular evolution of extrauterine high grade serous carcinoma. Gynecologic Oncology. PMID 31493898 DOI: 10.1016/j.ygyno.2019.08.029 |
0.263 |
|
| 2015 |
Russell S, Duquette M, Liu J, Drapkin R, Lawler J, Petrik J. Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 29: 576-88. PMID 25395453 DOI: 10.1096/fj.14-261636 |
0.263 |
|
| 2014 |
Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, Drapkin R, Urban N. Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1383-93. PMID 24789859 DOI: 10.1158/1055-9965.EPI-13-1361 |
0.26 |
|
| 2008 |
Nozaki K, Ogawa M, Williams JA, Lafleur BJ, Ng V, Drapkin RI, Mills JC, Konieczny SF, Nomura S, Goldenring JR. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology. 134: 511-22. PMID 18242217 DOI: 10.1053/J.Gastro.2007.11.058 |
0.258 |
|
| 2015 |
Lawrenson K, Li Q, Kar S, Seo JH, Tyrer J, Spindler TJ, Lee J, Chen Y, Karst A, Drapkin R, Aben KK, Anton-Culver H, Antonenkova N, Baker H, et al. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications. 6: 8234. PMID 26391404 DOI: 10.1038/Ncomms9234 |
0.257 |
|
| 2015 |
Mirkovic J, Elias K, Drapkin R, Barletta JA, Quade B, Hirsch MS. GATA3 expression in gestational trophoblastic tissues and tumours. Histopathology. PMID 25753145 DOI: 10.1111/his.12681 |
0.256 |
|
| 2023 |
Wang Y, Douville C, Chien YW, Wang BG, Chen CL, Pinto A, Smith SA, Drapkin R, Chui MH, Numan T, Vang R, Papadopoulos N, Wang TL, Shih IM. Aneuploidy Landscape in Precursors of Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38048050 DOI: 10.1158/1078-0432.CCR-23-0932 |
0.256 |
|
| 2016 |
Kuhn E, Wang TL, Doberstein K, Bahadirli-Talbott A, Ayhan A, Sehdev AS, Drapkin R, Kurman RJ, Shih IM. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 27443516 DOI: 10.1038/Modpathol.2016.101 |
0.253 |
|
| 2011 |
Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL, Drapkin R. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecologic Oncology. 123: 5-12. PMID 21683992 DOI: 10.1016/j.ygyno.2011.05.021 |
0.25 |
|
| 2008 |
Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecologic Oncology. 109: 168-73. PMID 18342932 DOI: 10.1016/j.ygyno.2008.01.012 |
0.249 |
|
| 2021 |
Zhang X, Devins K, Ko EM, Reyes MC, Simpkins F, Drapkin R, Schwartz LE, Yoon JY. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors. Gynecologic Oncology. PMID 33773808 DOI: 10.1016/j.ygyno.2021.03.019 |
0.246 |
|
| 2012 |
Sung CK, Yim H, Gu H, Li D, Andrews E, Duraisamy S, Li C, Drapkin R, Benjamin T. The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC. Plos One. 7: e46486. PMID 23029531 DOI: 10.1371/Journal.Pone.0046486 |
0.244 |
|
| 2016 |
Sherman M, Drapkin R, Horowitz NS, Crum CP, Friedman S, Kwon J, Levine DA, Shih IM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, et al. Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-grade Serous Carcinoma: A Review of the Evidence. Cancer Prevention Research (Philadelphia, Pa.). PMID 27221539 DOI: 10.1158/1940-6207.Capr-15-0384 |
0.242 |
|
| 2016 |
Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D. Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Reports. PMID 26774475 DOI: 10.1016/J.Celrep.2015.12.046 |
0.24 |
|
| 2012 |
Karst AM, Drapkin R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nature Protocols. 7: 1755-64. PMID 22936217 DOI: 10.1038/nprot.2012.097 |
0.238 |
|
| 2014 |
Bowtell DD, Drapkin R. Highlights from the 2014 American Association for Cancer Research Annual Meeting. Gynecologic Oncology. 134: 3-5. PMID 25089320 DOI: 10.1016/j.ygyno.2014.05.027 |
0.237 |
|
| 2013 |
Jiang SW, Chen H, Dowdy S, Fu A, Attewell J, Kalogera E, Drapkin R, Podratz K, Broaddus R, Li J. HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. International Journal of Molecular Sciences. 14: 22655-77. PMID 24252907 DOI: 10.3390/ijms141122655 |
0.237 |
|
| 2014 |
Elias KM, Labidi-Galy SI, Vitonis AF, Hornick JL, Doyle LA, Hirsch MS, Cramer DW, Drapkin R. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. Gynecologic Oncology. 132: 328-33. PMID 24342438 DOI: 10.1016/j.ygyno.2013.12.011 |
0.236 |
|
| 2016 |
Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 5: e1090075. PMID 27141347 DOI: 10.1080/2162402X.2015.1090075 |
0.23 |
|
| 2023 |
Restaino AC, Walz A, Vermeer SJ, Barr J, Kovács A, Fettig RR, Vermeer DW, Reavis H, Williamson CS, Lucido CT, Eichwald T, Omran DK, Jung E, Schwartz LE, Bell M, ... ... Drapkin R, et al. Functional neuronal circuits promote disease progression in cancer. Science Advances. 9: eade4443. PMID 37163587 DOI: 10.1126/sciadv.ade4443 |
0.23 |
|
| 2016 |
Perets R, Drapkin R. It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research. Cancer Research. 76: 10-7. PMID 26669862 DOI: 10.1158/0008-5472.CAN-15-1382 |
0.23 |
|
| 2020 |
Reavis HD, Chen HI, Drapkin R. Tumor Innervation: Cancer Has Some Nerve. Trends in Cancer. 6: 1059-1067. PMID 32807693 DOI: 10.1016/j.trecan.2020.07.005 |
0.23 |
|
| 2015 |
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, ... ... Drapkin R, et al. Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature. PMID 26503049 DOI: 10.1038/Nature15716 |
0.227 |
|
| 2022 |
Stover EH, Xiong N, Myers AP, Tayob N, Engvold V, Polak M, Broaddus RR, Makker V, Drapkin R, Liu JF, Horowitz NS, Meric-Bernstam F, Aghajanian C, Coleman RL, Mills GB, et al. A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecologic Oncology Reports. 40: 100974. PMID 35434236 DOI: 10.1016/j.gore.2022.100974 |
0.227 |
|
| 2011 |
Kondratiev S, Duraisamy S, Unitt CL, Green MR, Pinkus GS, Shipp MA, Kutok JL, Drapkin RI, Rodig SJ. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. The American Journal of Surgical Pathology. 35: 1531-9. PMID 21921781 DOI: 10.1097/Pas.0B013E31822Bd476 |
0.223 |
|
| 2019 |
Lucido CT, Wynja E, Madeo M, Williamson CS, Schwartz LE, Imblum BA, Drapkin R, Vermeer PD. Innervation of cervical carcinoma is mediated by cancer-derived exosomes. Gynecologic Oncology. PMID 31003747 DOI: 10.1016/j.ygyno.2019.04.651 |
0.22 |
|
| 2023 |
Hippen AA, Omran DK, Weber LM, Jung E, Drapkin R, Doherty JA, Hicks SC, Greene CS. Performance of computational algorithms to deconvolve heterogeneous bulk ovarian tumor tissue depends on experimental factors. Genome Biology. 24: 239. PMID 37864274 DOI: 10.1186/s13059-023-03077-7 |
0.215 |
|
| 2012 |
Manchanda R, Drapkin R, Jacobs I, Menon U. The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Gynecologic Oncology. 124: 185-91. PMID 22019526 DOI: 10.1016/j.ygyno.2011.10.017 |
0.21 |
|
| 2015 |
Montal ED, Dewi R, Bhalla K, Ou L, Hwang BJ, Ropell AE, Gordon C, Liu WJ, DeBerardinis RJ, Sudderth J, Twaddel W, Boros LG, Shroyer KR, Duraisamy S, Drapkin R, et al. PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. Molecular Cell. PMID 26481663 DOI: 10.1016/j.molcel.2015.09.025 |
0.206 |
|
| 2013 |
Howitt BE, Nucci MR, Drapkin R, Crum CP, Hirsch MS. Stathmin-1 expression as a complement to p16 helps identify high-grade cervical intraepithelial neoplasia with increased specificity. The American Journal of Surgical Pathology. 37: 89-97. PMID 23211296 DOI: 10.1097/PAS.0b013e3182753f5a |
0.205 |
|
| 2022 |
Balood M, Ahmadi M, Eichwald T, Ahmadi A, Majdoubi A, Roversi K, Roversi K, Lucido CT, Restaino AC, Huang S, Ji L, Huang KC, Semerena E, Thomas SC, Trevino AE, ... ... Drapkin R, et al. Nociceptor neurons affect cancer immunosurveillance. Nature. PMID 36323780 DOI: 10.1038/s41586-022-05374-w |
0.203 |
|
| 2008 |
Bossuyt V, Medeiros F, Drapkin R, Folkins AK, Crum CP, Nucci MR. Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. 27: 390-7. PMID 18580316 DOI: 10.1097/PGP.0b013e3181639a82 |
0.202 |
|
| 2019 |
Belur Nagaraj A, Joseph P, Ponting E, Fedorov Y, Singh S, Cole A, Lee W, Yoon E, Baccarini A, Scacheri P, Buckanovich R, Adams DJ, Drapkin R, Brown BD, DiFeo A. A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs. Stem Cell Reports. 12: 122-134. PMID 30629937 DOI: 10.1016/J.Stemcr.2018.12.002 |
0.201 |
|
| 2022 |
Bolton KL, Chen D, Corona de la Fuente RI, Fu Z, Murali R, K Bel M, Tazi Y, Cunningham JM, Chan ICC, Wiley BJ, Moukarzel LA, Winham SJ, Armasu SM, Lester J, Elishaev E, ... ... Drapkin R, et al. Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35816189 DOI: 10.1158/1078-0432.CCR-21-3817 |
0.194 |
|
| 2015 |
Liu Y, Qiang W, Xu X, Dong R, Karst AM, Liu Z, Kong B, Drapkin RI, Wei JJ. Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells. Oncotarget. PMID 26472020 DOI: 10.18632/oncotarget.5493 |
0.191 |
|
| 2014 |
Esselen KM, Ng SK, Hua Y, White M, Jimenez CA, Welch WR, Drapkin R, Berkowitz RS, Ng SW. Endosalpingiosis as it relates to tubal, ovarian and serous neoplastic tissues: an immunohistochemical study of tubal and Müllerian antigens. Gynecologic Oncology. 132: 316-21. PMID 24333360 DOI: 10.1016/j.ygyno.2013.12.007 |
0.189 |
|
| 2021 |
Lin J, Guo D, Liu H, Zhou W, Wang C, Müller I, Kossenkov AV, Drapkin R, Bitler BG, Helin K, Zhang R. The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. Cancer Immunology Research. PMID 34848497 DOI: 10.1158/2326-6066.CIR-21-0754 |
0.167 |
|
| 2007 |
Nucci MR, Drapkin R, Cin PD, Fletcher CDM, Fletcher JA. Distinctive cytogenetic profile in benign metastasizing leiomyoma: Pathogenetic implications American Journal of Surgical Pathology. 31: 737-743. PMID 17460458 DOI: 10.1097/01.pas.0000213414.15633.4e |
0.165 |
|
| 2015 |
Dreaden EC, Kong YW, Morton SW, Correa S, Choi KY, Shopsowitz KE, Renggli K, Drapkin R, Yaffe MB, Hammond PT. Tumor-Targeted Synergistic Blockade of MAPK and PI3K From a Layer-by-Layer Nanoparticle. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26034127 DOI: 10.1158/1078-0432.Ccr-15-0013 |
0.155 |
|
| 2021 |
Yekelchyk M, Madan E, Wilhelm J, Short KR, Palma AM, Liao L, Camacho D, Nkadori E, Winters MT, Rice ES, Rolim I, Cruz-Duarte R, Pelham CJ, Nagane M, Gupta K, ... ... Drapkin R, et al. Flower lose, a cell fitness marker, predicts COVID-19 prognosis. Embo Molecular Medicine. e13714. PMID 34661368 DOI: 10.15252/emmm.202013714 |
0.152 |
|
| 2015 |
Novak M, Lester J, Karst AM, Parkash V, Hirsch MS, Crum CP, Karlan BY, Drapkin R. Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. Gynecologic Oncology. 139: 104-11. PMID 26206555 DOI: 10.1016/J.Ygyno.2015.07.100 |
0.145 |
|
| 2003 |
Groisman R, Polanowska J, Kuraoka I, Sawada J, Saijo M, Drapkin R, Kisselev AF, Tanaka K, Nakatani Y. The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell. 113: 357-67. PMID 12732143 |
0.139 |
|
| 2008 |
Drapkin R, Clauss A, Skates S. Urokinase-type plasminogen activator receptor: a beacon of malignancy? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5643-5. PMID 18794069 DOI: 10.1158/1078-0432.CCR-08-1557 |
0.137 |
|
| 2013 |
Jones PM, Drapkin R. Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms. Frontiers in Oncology. 3: 217. PMID 23986883 DOI: 10.3389/fonc.2013.00217 |
0.136 |
|
| 2020 |
Knarr M, Avelar RA, Sekhar SC, Kwiatkowski LJ, Dziubinski ML, McAnulty J, Skala S, Avril S, Drapkin R, DiFeo A. miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling. Nature Communications. 11: 3231. PMID 32591511 DOI: 10.1038/s41467-020-17030-w |
0.123 |
|
| 2003 |
Drapkin RI, Genest DR, Holmes LB, Huang T, Vargas SO. Unilateral transverse arm defect with subterminal digital nubbins. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 6: 348-54. PMID 14692649 |
0.104 |
|
| 2008 |
Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP. Serous carcinogenesis in the fallopian tube: a descriptive classification. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. 27: 1-9. PMID 18156967 DOI: 10.1097/pgp.0b013e31814b191f |
0.069 |
|
| 2013 |
Manchanda R, Drapkin R, Menon U. There is a need for routine peritoneal cytology at RRSO. Gynecologic Oncology. 128: 149-50. PMID 23063757 DOI: 10.1016/j.ygyno.2012.09.031 |
0.067 |
|
| 2008 |
Garrett LA, Vargas SO, Drapkin R, Laufer MR. Does the fimbria have an embryologic origin distinct from that of the rest of the fallopian tube? Fertility and Sterility. 90: 2008.e5-8. PMID 18353321 DOI: 10.1016/j.fertnstert.2008.01.071 |
0.04 |
|
| 2008 |
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R, Anderson GL, Urban N. Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2647-55. PMID 18451228 DOI: 10.1158/1078-0432.CCR-07-1442 |
0.037 |
|
| Hide low-probability matches. |
